Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study

12Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

With the ever increasing cost and time required for drug development, new strategies for drug development are highly demanded, whereas repurposing old drugs has attracted much attention in drug discovery. In this paper, we introduce a new network pharmacology approach, namely PINA, to predict potential novel indications of old drugs based on the molecular networks affected by drugs and associated with diseases. Benchmark results on FDA approved drugs have shown the superiority of PINA over traditional computational approaches in identifying new indications of old drugs. We further extend PINA to predict the novel indications of Traditional Chinese Medicines (TCMs) with Liuwei Dihuang Wan (LDW) as a case study. The predicted indications, including immune system disorders and tumor, are validated by expert knowledge and evidences from literature, demonstrating the effectiveness of our proposed computational approach.

Cite

CITATION STYLE

APA

Wang, Y. Y., Bai, H., Zhang, R. Z., Yan, H., Ning, K., & Zhao, X. M. (2017). Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study. Oncotarget, 8(55), 93957–93968. https://doi.org/10.18632/oncotarget.21398

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free